Merck & Co., Inc. and Eisai Announce WELIREG(R) (belzutifan) Plus LENVIMA(R) (lenvatinib) Met Primary Endpoint of Progression-Free Survival (PFS) in Certain Previously Treated Patients With Advanced Renal Cell Carcinoma
RAHWAY, NJ and TOKYO, October 28, 2025 - (JCN Newswire via SeaPRwire.com) - Merck & Co., Inc., Rahway, NJ, USA (known as MSD outside of the United States and Canada)...
